26.11.2024 16:26:15
|
UroGen Announces Positive Complete Response Data For Long-Term Jelmyto Follow-Up Study
(RTTNews) - UroGen Pharma Ltd. (URGN), Tuesday announced data from a long-term follow-up study with Jelmyto for pyelocalyceal solution, an FDA approved for the treatment of low-grade, upper tract urothelial cancer in adult patients.
Among 71 patients involved in the OLYMPUS trial, 41 achieved a complete response after, primary chemoablation with Jelmyto and had a median duration of response of 47.8 months, with median follow-up of 28.1 months.
Currently, UroGen's stock is trading at $12.19, down 2.32 percent on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu UroGen Pharma Ltd Registered Shsmehr Nachrichten
05.11.24 |
Ausblick: UroGen Pharma verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu UroGen Pharma Ltd Registered Shsmehr Analysen
Aktien in diesem Artikel
UroGen Pharma Ltd Registered Shs | 8,75 | 0,00% |
|